Skip to content

Study Using Tumor Resection Tissue to Explore a New Immunotherapy Strategy for Liver Cancer

Mechanistic Study on Immunotherapy of Liver Cancer Using Zombie Cell-Delivered KLB Monoclonal Antibody Conjugates

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114066
Enrollment
Unknown
Registered
2025-12-08
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

A sample group of liver cancer tissues and adjacent tissues:None

Sponsors

Chongqing University Three Gorges Hospital(Chongqing Three Gorges Central Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years, regardless of gender; 2. Planning to undergo radical resection or percutaneous liver biopsy for liver cancer at the Third Gorges Hospital affiliated with Chongqing University, with sufficient adjacent non-cancerous tissue available according to the surgical plan; 3. Imaging or pathology indicates hepatocellular carcinoma (HCC), and conditions for collecting adjacent non-cancerous tissue are met; 4. The volunteer voluntarily agrees to participate in this study and signs the informed consent form; 5. Clinical condition is stable, meeting tissue collection requirements, with no major preoperative contraindications.

Exclusion criteria

Exclusion criteria: 1. Pathology cannot confirm cancer-adjacent tissue, or the tissue sample quality is insufficient to meet experimental requirements; 2. Combined severe underlying diseases (such as systemic immune diseases, active infections, etc.) that affect the assessment of tissue immune background; 3. Have undergone liver transplantation, or are currently receiving systemic immunosuppressive therapy; 4. Pregnant or breastfeeding women; 5. Refuse to sign the informed consent, or withdraw authorization after signing.

Design outcomes

Primary

MeasureTime frame
Expression levels of KLB-pathway molecules and their correlations with immune/cell-cycle markers;

Countries

China

Contacts

Public ContactXian Qin

Chongqing University Three Gorges Hospital(Chongqing Three Gorges Central Hospital)

qinxian224@163.com+86 23 4837281

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026